Monday morning, specialty pharmaceutical company Jazz Pharmaceuticals, Inc. (JAZZ) said Nathaniel Zilkha has been elected to the company's Board of Directors, effective October 4. The company also announced resignation of Adam Clammer from its Board of Directors effective October 3.The Palo Alto, California headquartered company said Zilkha is a Principal at Kohlberg Kravis Roberts & Co. L.P., where he is a member of the Health Care industry team. Prior to joining KKR earlier this year, he was a Vice President in the Principal Investment Area of Goldman Sachs, where he executed and monitored private equity investments on behalf of the GS Capital Partners family of funds and led the group's efforts in Healthcare and Life Sciences.JAZZ is currently down $0.26 or 1.93% and trades at $13.24.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.